Compare Carparts.Com Inc (PRTS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carparts.Com Inc vs Recursion Pharmaceuticals Inc — how do they compare? Carparts.Com Inc trades at $10.2 (market cap $72.26M), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 25.7× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| PRTS | RXRX | |
|---|---|---|
Market Cap | $72.26M | $1.86B |
Sector | Consumer Cyclical | Health |
52-Week High | $10.00 | $6.79 |
52-Week Low | $3.88 | $2.84 |
Enterprise Value | $85.23M | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarParts.com (PRTS) trades at $9.50, up 2.15% with strong technical momentum and bullish moving average signals. The company shows improving quarterly earnings performance with three consecutive beats, though it remains unprofitable with negative margins. Recent developments include a new $25 million credit facility and Nasdaq compliance restoration, while analyst sentiment leans positive with 60% buy ratings.
The outlook suggests cautious optimism given improving earnings trajectory and technical strength, but significant risks persist from sustained losses, negative cash flow, and competitive pressures. Investment appeal hinges on the company's ability to translate revenue stabilization into profitability while managing operational challenges in the automotive e-commerce sector.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
